Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-07-2010 | Original Paper

FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2010

Abstract

Background and purpose

Breast carcinoma is the most common cancer in female patients with a propensity for recurrence and metastases. The accuracy of ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), scintimammography (SMM) and positron emission tomography (PET) in diagnosing the recurrent and/or breast cancer has never been systematically assessed, and present systematic review was aimed at this issue.

Methods

MEDLINE and EMBASE were searched for articles dealt with detection of recurrent and/or metastatic breast cancer by US, CT, MRI, SMM or PET whether interpreted with or without the use of CT. Histopathologic analysis and/or close clinical and imaging follow-up for at least 6 months were used as golden reference. We extracted data to calculate sensitivity, specificity, summary receiver operating characteristic curves and area under the curve and to test for heterogeneity.

Result

In 42 included studies, US and MRI had highest pooled specificity (0.962 and 0.929, respectively); MRI and PET had highest pooled sensitivity (0.9500 and 0.9530, respectively). The AUC of US, CT, MRI, SMM and PET was 0.9251, 0.8596, 0.9718, 0.9386 and 0.9604, respectively. Results of pairwise comparison between each modality demonstrated that AUC of MRI and PET was higher than that of US or CT, p < 0.05. No statistical significance was found between MRI and PET. There was heterogeneity among studies and evidence of publication bias.

Conclusion

In conclusion, MRI seemed to be a more useful supplement to current surveillance techniques to assess patients with suspected recurrent and/or metastatic breast cancer. If MRI shows an indeterminate or benign lesion or MRI was not applicable, FDG-PET could be performed in addition.

Aide N, Huchet V, Switsers O, Heutte N (2007) Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun 28(4):267–272PubMedCrossRef

American Cancer Society (2002) Breast cancer facts and figures. American Cancer Society, Atlanta, GA, pp 9–10

Armington WG, Harnsberger HR, Osborn AG, Seay AR (1987) Radiographic evaluation of brachial plexopathy. Am J Neuroradiol 8(2):361–367PubMed

Bäz E, Madjar H, Reuss C, Vetter M (2000) The role of enhanced Doppler ultrasound in differentiation of benign vs. malignant scar lesion after breast surgery for malignancy. Ultrasound Obstet Gynecol 15(5):377–382PubMedCrossRef

Belli P, Pastore G, Romani M, Terribile D, Canadè A (2002) Role of magnetic resonance imaging in the diagnosis of recurrence after breast conserving therapy. Rays 27(4):241–257PubMed

Berlin JA (1997) Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 350(9072):185–186PubMedCrossRef

Bilbey JH, Lamond RG, Mattrey RF (1994) MR imaging of disorders of the brachial plexus. J Magn Reson Imag 4(1):13–18CrossRef

Bongers V, Perre C, de Hooge P (2004) The use of scintimammography for detecting the recurrence of loco-regional breast cancer: histopathologically proven results. Nucl Med Commun 25(2):145–149PubMedCrossRef

Bruneton JN, Caramella E, Héry M, Aubanel D (1986) Axillary lymph node metastases in breast cancer: preoperative detection with US. Radiology 158(2):325–326PubMed

Cancer Research Campaign (1996) Breast cancer. Cancer Research Campaign, UK, fact sheet

Cwikla JB, Buscombe JR, Parbhoo SP, Kelleher SM (1998) Use of 99Tcm-MIBI in the assessment of patients with suspected recurrent breast cancer. Nucl Med Commun 19(7):649–655PubMedCrossRef

De Cicco C, Trifirò G, Baio S, Sierra ML, Pizzamiglio M (2004) Clinical utility of 99mTc-Sestamibi scintimammography in the management of equivocal breast lesions. Cancer Biother Radiopharm 19(5):621–626PubMed

de Verdier HJ, Colletti PM, Terk MR (1993) MRI of the brachial plexus: a review of 51 cases. Comput Med Imaging Graph 17(1):45–50PubMedCrossRef

Deeks JJ (2001) Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323(7305):157–162PubMedCrossRef

Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36(10):1766–1774PubMed

Dershaw DD, McCormick B, Osborne MP (1992) Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 70(2):493–496PubMedCrossRef

Devillé WL, Bezemer PD, Bouter LM (2000) Publications on diagnostic test evaluation in family medicine journals: an optimal search strategy. J Clin Epidemiol 53(1):65–69PubMedCrossRef

Devillé WL, Buntinx F, Bouter LM, Montori VM (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9PubMedCrossRef

Drew PJ, Kerin MJ, Turnbull LW, Imrie M (1998) Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast. Ann Surg Oncol 5(3):265–270PubMedCrossRef

Eubank WB, Mankoff DA, Takasugi J, Vesselle H (2001) 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19(15):3516–3523PubMed

Eubank WB, Mankoff DA, Vesselle HJ, Eary JF (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22(1):5–17PubMed

Eubank WB, Mankoff D, Bhattacharya M, Gralow J (2004) Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 183(2):479–486

Fisher ER, Anderson S, Tan-Chiu E, Fisher B (2001) Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91(8 Suppl):1679–1687PubMedCrossRef

Fleiss JL, Levin B, Paik MC (2003) The comparison of proportions from several independent samples: estimation of the marginal mean proportion. In: Fleiss JL, Levin B, Paik MC (eds) Statistical methods for rates and proportions, 3rd edn. Wiley, New Jersey, pp 212–217

Fueger BJ, Weber WA, Quon A, Crawford TL (2005) Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imag Biol 7(5):369–376CrossRef

Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I (2003) F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38(5):250–256PubMedCrossRef

Gilles R, Guinebretière JM, Shapeero LG, Lesnik A (1993) Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 188(2):473–478PubMed

Goerres GW, Michel SC, Fehr MK, Kaim AH (2003) Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13(7):1635–1644PubMedCrossRef

Hagay C, Cherel PJ, de Maulmont CE, Plantet MM (1996) Contrast-enhanced CT: value for diagnosing local breast cancer recurrence after conservative treatment. Radiology 200(3):631–638PubMed

Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM (1999) Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 210(3):807–814PubMed

Hatteville L, Mahe C, Hill C (2002) Prediction of the long-term survival in breast cancer patients according to the present oncological status. Stat Med 21(16):2345–2354PubMedCrossRef

Haug AR, Schmidt GP, Klingenstein A, Heinemann V (2007) F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 31(4):629–634PubMedCrossRef

Heywang-Köbrunner SH, Schlegel A, Beck R, Wendt T (1993) Contrast-enhanced MRI of the breast after limited surgery and radiation therapy. J Comput Assist Tomogr 17(6):891–900PubMedCrossRef

Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I ² index? Psychol Methods 11(2):193–206PubMedCrossRef

Isasi CR, Moadel RM, Blaufox MD (2005) A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90:105–112PubMedCrossRef

Kamby C, Vejborg I, Kristensen B, Olsen LO (1988) Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer 62(10):2226–2233PubMedCrossRef

Kamel EM, Wyss MT, Fehr MK, von Schulthess GK (2003) [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129(3):147–153PubMed

Kao CH, Wang SJ, Liu TJ (1994) The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 21(5):432–436PubMedCrossRef

Kao CH, Hsieh JF, Tsai SC, Ho YJ (2000) Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20(3B):2189–2192PubMed

Khalkhali I, Cutrone J, Mena I, Diggles L (1995) Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 36(10):1784–1789PubMed

Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef

Kim TS, Moon WK, Lee DS, Chung JK (2001) Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25(7):829–834PubMedCrossRef

Kneeland JB, Kellman GM, Middleton WD, Cates JD (1987) Diagnosis of diseases of the supraclavicular region by use of MR imaging. Am J Roentgenol 148(6):1149–1151

Lamuraglia M, Lassau N, Garbay JR, Mathieu MC (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: a prospective phase II study. Eur J Radiol 56(3):376–381 [Epub 2005 Jul 7]PubMedCrossRef

Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH (2005) Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 92(11):1363–1367PubMedCrossRef

Lee VW, Sax EJ, McAneny DB, Pollack S (1993) A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 34(12):2095–2100PubMed

Liu CS, Shen YY, Lin CC, Yen RF, Kao CH (2002) Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32(7):244–247PubMedCrossRef

McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP (1992) Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 182(2):319–323PubMed

Melani E, Sardanelli F, Ottonello C, Parodi RC (1995) Magnetic resonance mammography in suspected tumor recurrences. Radiol Med (Torino) 89(3):219–224 (article in Italian)

Moon DH, Maddahi J, Silverman DH, Glaspy JA (1998) Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39(3):431–435PubMed

Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293–1316PubMedCrossRef

Moskovic E, Curtis S, A’Hern RP, Harmer CL (1992) The role of diagnostic CT scanning of the brachial plexus and axilla in the follow-up of patients with breast cancer. Clin Oncol (R Coll Radiol) 4(2):74–77

Muüller RD, Barkhausen J, Sauerwein W, Langer R (1998) Assessment of local recurrence after breast-conserving therapy with MRI. J Comput Assist Tomogr 22(3):408–412PubMedCrossRef

Nomura Y, Tsutsui S, Murakami S, Takenaka Y (1999) Prognostic impact of second cancer on the survival of early breast cancer patients. Int J Oncol 14(6):1103–1109PubMed

Orel SG, Troupin RH, Patterson EA, Fowble BL (1992) Breast cancer recurrence after lumpectomy and irradiation: role of mammography in detection. Radiology 183(1):201–206PubMed

Parker S, Tong T, Bolden S, Wingo PA (1997) Cancer statistics, 1997. CA Cancer J Clin 47:5–27PubMedCrossRef

Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, Alberini JL (2001) Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2(3):229–234PubMedCrossRef

Piperkova E, Raphael B, Altinyay ME, Castellon I (2007) Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 32(6):429–434PubMedCrossRef

Preda L, Villa G, Rizzo S, Bazzi L (2006) Magnetic resonance mammography in the evaluation of recurrence at the prior lumpectomy site after conservative surgery and radiotherapy. Breast Cancer Res 8(5):R53

Qayyum A, MacVicar AD, Padhani AR, Revell P (2000) Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. Radiology 214(3):837–842PubMed

Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L (2006) The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107(11):2545–2551PubMedCrossRef

Rajkovaca Z, Vuleta G, Matavulj A, Kovacević P (2007) 99m Tc-sestamibi scintimammography in detection of recurrent breast cancer. Bosn J Basic Med Sci 7(3):256–260PubMed

Riebe E, Günther K, Schulz K, Köhler G (2007) Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer—diagnostic yield of palpation, mammography and ultrasonography. Ultraschall Med 28(4):394–400PubMedCrossRef

Rieber A, Merkle E, Zeitler H, Görich J, Kreienberg R (1997) Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 21(5):780–784PubMedCrossRef

Rissanen TJ, Mäkäräinen HP, Mattila SI, Lindholm EL (1993) Breast cancer recurrence after mastectomy: diagnosis with mammography and US. Radiology 188(2):463–467PubMed

Sackett DL, Haynes RB (2002) The architecture of diagnostic research. BMJ 324(7336):539–541PubMedCrossRef

Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V (2008) Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET–CT. Eur J Radiol 65(1):47–58PubMedCrossRef

Shin JH, Han BK, Choe YH, Nam SJ, Park W (2005) Ultrasonographic detection of occult cancer in patients after surgical therapy for breast cancer. J Ultrasound Med 24(5):643–649PubMed

Siggelkow W, Zimny M, Faridi A, Petzold K (2003) The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23(2C):1859–1867PubMed

Siggelkow W, Rath W, Buell U, Zimny M (2004) FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imag 31(Suppl 1):S118–S124

Soerjomataram I, Louwman MW, Ribot JG, Roukema JA (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107(3):309–330PubMedCrossRef

Stomper PC, Recht A, Berenberg AL, Jochelson MS (1987) Mammographic detection of recurrent cancer in the irradiated breast. Am J Roentgenol 148(1):39–43

Stuhrmann M, Aronius R, Schietzel M (2000) Tumor vascularity of breast lesions: potentials and limits of contrast-enhanced Doppler sonography. Am J Roentgenol 175(6):1585–1589

Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M (2002) Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46(2):113–121PubMed

Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imag 33(3):254–262 [Epub 2005 Oct 29]CrossRef

Ternier F, Houvenaeghel G, Lecrivain F, Brigand BL (2006) Computed tomography in suspected local breast cancer recurrence. Breast Cancer Res Treat 100(3):247–254PubMedCrossRef

The GIVIO Investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 271(20):1587–1592CrossRef

Tiling R, Khalkhali I, Sommer H, Linke R (1998) Limited value of scintimammography and contrast-enhanced MRI in the evaluation of microcalcification detected by mammography. Nucl Med Commun 19(1):55–62PubMedCrossRef

Tolmos J, Cutrone JA, Wang B, Vargas HI (1998) Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. J Natl Cancer Inst 90(11):846–849PubMedCrossRef

Usmani S, Niaz K, Maseeh-Uz-Zaman, Niyaz K (2007) Chest wall recurrence of breast cancer demonstrated on 99mTc-MIBI scintimammography. Nucl Med Commun 28(11):842–846PubMedCrossRef

von Fournier D, Anton H, Junkermann H, Bastert G, van Kaick G (1993) Breast cancer screening. State of the art and introduction to preventive measures. Radiologe 33:227

Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028–2037PubMedCrossRef

Webb WR, Gatsonis C, Zerhouni EA, Heelan RT (1991) CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178(3):705–713PubMed

Weir L, Worsley D, Bernstein V (2005) The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 11(3):204–209PubMedCrossRef

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25PubMedCrossRef

Winehouse J, Douek M, Holz K, Madjar H (1999) Contrast-enhanced colour Doppler ultrasonography in suspected breast cancer recurrence. Br J Surg 86(9):1198–1201PubMedCrossRef

Wolfort RM, Li BD, Johnson LW, Turnage RH (2006) The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg 30(8):1422–1427PubMedCrossRef

Yang SK, Cho N, Moon WK (2007) The role of PET/CT for evaluating breast cancer. Korean J Radiol 8(5):429–437PubMedCrossRef

Yilmaz MH, Esen G, Ayarcan Y (2007) The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy. Diagn Interv Radiol 13:13–18PubMed

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31PubMedCrossRef

Title: FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis
Publication date: 01-07-2010
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0746-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis

Abstract

Background and purpose

Methods

Result

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and purpose

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2010

Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer

Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors

Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer

The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page